Blonanserin: a review of its use in the management of schizophrenia (Q34089641)

30 July 2017

1 reference

title

Blonanserin: a review of its use in the management of schizophrenia (English)

1 reference

30 July 2017

0 references

2

Gillian M Keating

1 reference

30 July 2017

1

Emma D Deeks

1 reference

30 July 2017

1 January 2010

1 reference

30 July 2017

1 reference

30 July 2017

24

1 reference

30 July 2017

1

1 reference

30 July 2017

65-84

1 reference

https://scigraph.springernature.com/pub.10.2165/11202620-000000000-00000

30 July 2017

0 references

cites work

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

12 December 2020

Adverse effects of atypical antipsychotics : differential risk and clinical implications

1 reference

12 December 2020

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

1 reference

12 December 2020

Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain

1 reference

12 December 2020

Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.

1 reference

12 December 2020

Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.

1 reference

12 December 2020

Dosing frequency and adherence to antipsychotic medications.

1 reference

12 December 2020

The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics

1 reference

12 December 2020

Receptor pharmacology of neuroleptics: relation to clinical effects

1 reference

12 December 2020

Partial compliance and patient consequences in schizophrenia: our patients can do better.

1 reference

12 December 2020

Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity

1 reference

12 December 2020

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

12 December 2020

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

1 reference

12 December 2020

Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice

1 reference

12 December 2020

The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity

1 reference

12 December 2020

10.2165/11202620-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20030420

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

20030420